Soy, isoflavone consumption not associated with endometrial cancer risk
the ONA take:
According to a new study published in the journal BJOG, an international journal obstetrics and gynecology, researchers from the National Cancer Center in Tokyo, Japan, have found that soy food/isoflavone consumption is not associated with endometrial cancer risk in Japanese women.
For the study, researchers sought to investigate whether a correlation exists between soy food/isoflavone consumption and endometrial cancer risk because consumption of soy food in Japan is very high while endometrial cancer incidence is very low.
Researchers conducted a prospective cohort study that included 49,121 Japanese women aged 45 to 74 years. Participants completed self-administered food frequency questionnaires that assessed intake of soy foods and isoflavones between 1995 and 1998, followed by a 5-year follow-up survey.
Results showed that during an average follow-up of 12.1 years, there were 112 cases of newly diagnosed endometrial cancer. The researchers found no association between soy food and isoflavone consumption and endometrial cancer risk.
Soy food/isoflavone consumption is not associated with endometrial cancer risk in Japanese women.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|